Type 1 Diabetes

Previous research links type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD).

A professional discussion on diagnosing type 1 diabetes based on autoimmune antibodies, oral glucose tolerance test results, fasting glucose, and hemoglobin A1C levels.

Similar burdens were observed among both children with a diagnosis of type 1 diabetes (T1D) and their informal caregivers, both at the time of diagnosis and when the disease was already established.

Individual variations in cognitive performance based on fluctuating glucose levels were observed, necessitating further research on the topic.

This finding on continuous glucose monitoring (CGM) remained even after the researchers adjusted for glycemic control according to HbA1C levels.

This secondary analysis follows initial results from a phase 3 trial, which suggested that vitamin D supplementation with ergocalciferol improved insulin sensitivity, subsequently slowing the rise of insulin requirements in patients who have type 1 diabetes (T1D).

Increased interest in screening for the genetic risk of type 1 diabetes (T1D) has been driven by factors including the introduction of immune interventions.

However, prevalence was found to plateau over time, suggesting neuropathic pain may be isolated or intermittent events in some patients with type 1 diabetes.

The pump had varying success in reaching recommended glycemic targets among the study participants with type 1 diabetes (T1D).

Outside of genetics, which has a well-documented link to the risk of type 1 diabetes (T1D), investigators detail available research spanning a variety of factors, including viral infections, pesticide exposure, and the gut microbiome.

Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes.

The findings follow endorsement of the screening measure from the American Diabetes Association, which recommended the practice to identify patients who have type 1 diabetes (T1D) who could benefit from targeted strategies to prevent symptomatic heart failure (HF).

Investigators say adolescents had difficulty adhering to the workbook-based program, but the authors said changes—and perhaps a digital format—could improve the program’s performance.

Having multiple readmissions for diabetes ketoacidosis (DKA) was more likely to occur among patients with type 1 diabetes (T1D) with substance use disorder or who previously were incarcerated.

A new study challenges assumptions about the role of dietary protein and fat in managing blood glucose fluctuations, known as glycemic variability.

A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among young adult patients with type 1 diabetes (T1D).

In a systematic review and meta-analysis, real-time continuous glucose monitoring (CGM) demonstrated benefits in terms of time in range, hypoglycemia, and hyperglycemia among patients with type 1 diabetes (T1D).

A study of adolescents with type 1 diabetes (T1D) found that real-time continuous glucose monitoring (CGM) with a predictive hypoglycemia alarm reduced the time spent below range.

A Finnish study found maternal type 1 diabetes (T1D) to be associated with a significantly higher risk of any congenital heart defect (CHD) in offspring, and that maternal overweight or obesity was associated with certain CHDs in offspring.

In recently published data from the phase 3 PROTECT trial, teplizumab slowed the progression of type 1 diabetes in children and adolescents.

Mendelian randomization analyses demonstrated a causal relationship between hypothyroidism and diabetes, along with its related microvascular complications.

Our top-read type 1 diabetes articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

The highest incidence of pediatric type 1 diabetes (T1D) over the past 22 years was seen in Finland, high-income North American regions, and children aged 5 to 14 years.